Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome.
M U
MU
Shad
S H
SH
Preskorn
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D001921:Brain / Q000187:drug effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D016651:Lithium Carbonate / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D009459:Neuroleptic Malignant Syndrome / Q000097:blood* / Q000175:diagnosis; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D010546:Perphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D014196:Trazodone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
D014150:Antipsychotic Agents; D016651:Lithium Carbonate; D017374:Paroxetine; D010546:Perphenazine; D017367:Selective Serotonin Reuptake Inhibitors; D014196:Trazodone